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ABSTRACT
Introduction: Cutaneous side effects caused by
epidermal growth factor receptor (EGFR)
inhibitors occurred in 45–100% of patients
which may lead to therapy modification or
interruption. This study aimed to evaluate
cutaneous side effects and transepidermal
water loss (TEWL) values in non-small cell
lung carcinoma (NSCLC) patients who
received gefitinib EGFR inhibitor.
Methods: A descriptive observational study
with cross-sectional design and a consecutive
sampling method was conducted from 1
February to 4 March 2016. Eleven NSCLC
patients with EGFR mutation who visited the
Hemato-Oncology Clinic/Internal Medicine
Department, Dr. Hasan Sadikin General
Hospital, Bandung, Indonesia, were assessed
through history taking, physical examination,
and TEWL examination using Tewameter.
Results: Ten of the eleven patients experienced
cutaneous side effects. The most frequently
observed was xerosis cutis (8/10 patients),
followed by acneiform eruptions (7/10
patients), and paronychia (3/10 patients).
None of these patients experienced hair
changes, mucositis, or drug hypersensitivity.
Mean TEWL value of these patients was higher
than normal (11.205 ± 1.881 g/m2/h).
Conclusions: Patients who received gefitinib
EGFR inhibitor experienced cutaneous side
effects including xerosis cutis, acneiform
eruptions, and paronychia, and have mean
TEWL values higher than normal. Therefore, it
might affect the skin barrier function.
Keywords: Cutaneous side effects; Epidermal
growth factor receptor inhibitor;
Transepidermal water loss
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INTRODUCTION
Lung carcinoma is one of the leading causes of
worldwide mortality [1–3]. One type, non-small
cell lung carcinoma (NSCLC), accounts for 85%
of all lung cancers [4]. Prior studies have
demonstrated the important role of epidermal
growth factor receptor (EGFR), a tyrosine kinase
growth factor family transmembrane
glycoprotein [5–7], in which gene mutation
happens in 40–80% of all NSCLC patients
[1, 4, 8].
Gefitinib (Iressa) is an oral tyrosine kinase
EGFR inhibitor [2, 9, 10] approved by the Food
and Drug Administration, USA, as the
monotherapy for both local and metastatic
NSCLC [11, 12]. Cutaneous toxicities are the
most common forms of EGFR inhibitor side
effects [13], affecting approximately 45–100% of
patients [13, 14] and varying from
papulopustular rashes on the face and upper
side trunk to xerosis cutis, paronychia, hair
disorder, and pruritus [14, 15], leading to
treatment modification or interruption in
8–17% of patients [14]. These side effects are
related to the EGFR expression role in
promoting the proliferation, survival, motility,
and regulation of the differentiation and
keratinization [16] of human skin cells [17],
such as keratinocytes [18], corneocytes, sweat
glands and hair follicles [5].
Transepidermal water loss is a measurement
of the absolute rate of body water loss which
acts as a parameter reflecting permeability
barrier status and which may discover
disturbances in the skin protective function at
an early stage, even before they are visible [19].
Due to the limited number of clinical studies on
the cutaneous side effects and TEWL value
measurements in patients receiving EGFR
inhibitor, the authors were interested to
conduct this study.
METHODS
A descriptive observational study with
cross-sectional design and a consecutive
sampling method was conducted from 1
February to 4 March 2016. We collected
NSCLC patients from the Hemato-Oncology
Clinic/Internal Medicine Department, Dr.
Hasan Sadikin General Hospital, Bandung,
Indonesia, medical records. We included all
patients with positive EGFR mutation who were
on gefitinib as the current main therapy (and
had been diagnosed and treatment has been
started prior to the study) and those who signed
the informed consent form. We excluded
patients who had other dermatologic disorder
histories before gefitinib consumption or on the
examination location (volar surface of both
arms); those who used topical medication,
medical devices, and other occlusive
substances on examination location; those
who did not follow-up; and those who refused
to participate in this study. Patients were
classified according to WHO age groups and
their treatment intervals.
History taking and physical examination
were conducted while patients were in resting
phase (20 min) before the TEWL value
measurement. A Tewameter TM 300,
(Khazaka 2003) was used to measure TEWL
values in 30 s, thrice on the volar surface of
both arms, at room temperature 20–22 C and
air humidity 40–60%. Patient bilateral arm
TEWL average value was calculated, with a
normal lower arm surface TEWL range value
reference of 2.26 ± 1.36 g/m2/h. All procedures
followed were in accordance with the ethical
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standards of the responsible committee on
human experimentation (institutional approval
from Medical Research Ethical Committee,
Medical Faculty-Universitas Padjadjaran/Dr.
Hasan Sadikin General Hospital) and with the
Helsinki Declaration of 1964, as revised in 2013.
Written informed consent was obtained from
all patients to be included in the study.
RESULTS
Participants
The Hemato-Oncology Clinic/Internal Medicine
Department recorded that there were 37 NSCLC
patients using gefitinib by the year 2014. At the
time this study was conducted, 16 patients were
confirmed dead, another 14 patients did not
make follow-up visits or had no valid contact
number and address, another 2 patients had
moved out of the town, and the last 1 stopped
her gefitinib regimen. Only 4 former patients
came to our clinic and agreed to participate in
our study along with other 7 new patients.
There were 2 new patients who were reluctant
to participate (see Fig. 1).
Eleven lung adenocarcinoma patients with
positive EGFR mutation, consisted of 6 male
and 5 female patients within age group
[40 years old were included in this study. The
youngest patient was 43 and the eldest was
84 years (mean 62.18 ± 13.27). Most patients
were [65. The shortest interval of gefitinib
consumption was 1 week, while the longest
was 18 months (average 10.27 ± 6.14 months).
Most participants had been using gefitinib for
[6 months (7/11 patients). According to
physical examination, 10 patients has
experienced at least one cutaneous disorder
manifestation. One male patient who
belonged to the [65 years group had been
using gefitinib for just 1 week and had not
complained of any cutaneous side effect, which
was confirmed by his physical examination (see
Table 1).
Cutaneous Side Effects and TEWL Results
Female patients had more xerosis cutis (5/5
patients) and paronychia (2/5 patients), while
male patients experienced more acneiform
eruption (4/5 patients). Xerosis cutis and
acneiform eruption were the two most
common cutaneous findings in every age
group, while paronychia was detected mostly
in the 40–44 and 60–64 age groups. As
mentioned previously, one patient who had
only been using gefitinib for 1 week (\1 month)
showed no cutaneous side effects manifestation
(see Tables 2, 3).
Fig. 1 Study participants enrolment
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The mean TEWL value measurement on both
volar surfaces of patients was 11.205 (±1.881)
g/m2/h (see Table S1 in the supplementary
material for details). Mean TEWL measurement
values were higher in male than in female
patients. Based on age group, TEWL values were
highest in 40–44 years group compared to other
age groups. TEWL value was also the highest in
the gefitinib consumption group of 5–6 months
and lowest in the group of \1 month (see
Table 3).
DISCUSSION
Cutaneous Side Effect Manifestations
in NSCLC Patients with EGFR Mutation
Who Received Gefitinib
This study showed that 10/11 patients
experienced cutaneous side effects which
confirmed the previous literature, Wang et al.
[17], who revealed that 67.6% of lung
carcinoma patients with unknown EGFR
mutation status who received gefitinib in
Taiwan experienced cutaneous side effects.
According to Cohen et al. [12], the level of
EGFR mutation was assumed to be associated
with cutaneous side effects, because of the
elevated EGFR inhibition in the skin tissue.
Some patients were more susceptible to side
effects of EGFR inhibition, due to DNA
polimorphism of normal cells and carcinoma.
The most common cutaneous side effects
findings in this study were xerosis cutis,
followed by acneiform eruption, and
paronychia (see Figs. 2, 3, 4). According to
Roe, xerosis cutis developed in 100% of
patients after 6 months consuming the EGFR
inhibitor [20]. This might have happened
Table 1 Cutaneous side effect manifestations examination
result





40–44 1 Mean (SD): 62.18 (13.27)
45–49 1 Median: 62.00




Geﬁtinib consumption interval (months)
\1 1
1–2 0 Mean (SD): 10.27 (6.14)
2–3 1 Median: 12.00







Table 2 Cutaneous side effect manifestations examination
result




Others (hair disorder, mucositis,
hypersensitivity reactions)
0
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because, in normal conditions, it took 14 days
for epidermal cells to reach the stratum
corneum [14], and thus keratinocyte
differentiation disorder due to EGFR inhibitor
causing xerosis cutis was a late-onset side effect
[14, 21].
Acneiform eruption in this study was found
in almost every age group and was more
common in male patients, as demonstrated by
previous studies, due to the outdoor activities
that exposed males to ultra violet (UV) light
more than females [22]. Ultra violet light
exposure resulted in keratinocyte destruction












Male (n = 6) 3 4 1 11.64 (±2.34)
Female (n = 5) 5 3 2 10.68 (±1.17)
Age group (years)
40–44 (n = 1) 1 1 1 15.72 (±0)
45–49 (n = 1) 1 1 0 11.12 (±0)
50–54 (n = 2) 1 1 0 11.03 (±0.59)
55–59 (n = 0) 0 0 0 –
60–64 (n = 3) 2 1 2 10.78 (±1.71)
C65 (n = 4) 3 3 0 10.5 (±1.44)
Geﬁtinib consumption interval (months)
\1 (n = 1) 0 0 0 8.55 (±0)
1–2 (n = 0) 0 0 0 –
2–3 (n = 1) 0 1 0 11.98 (±0)
3–4 (n = 0) 0 0 0 –
4–5 (n = 0) 0 0 0 –
5–6 (n = 2) 2 2 1 13 (±3.84)
[6 (n = 7) 6 4 2 10.96 (±1.01)
Fig. 2 Acneiform eruption on patient’s chest
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through photoproducts and reactive oxygen
species (ROS) formation. Hence, that effect
might become worse when EGFR inhibition
occurred simultaneously [14].
Inhibition of EGFR resulted in distortion of
skin cell growth, epithelial cells
differentiation, and skin protection function
[23], including to UV exposure protection
[13]. Moreover, EGFR inhibition led to
increased inflamatory chemokin expression
which then recruited and resulted in
inflammatory cells infiltration, especially in
the follicle infundibulum [24].
Wang et al. [17] revealed the correlation
between xerosis cutis and paronychia, and that
xerosis cutis is a risk factor for paronychia, since
xerosis cutis induced by the EGFR inhibitor
might cause desquamation with subsequent
sticking between the nail plate and the
neighboring skin, inducing chronic irritation
and inflammation [25]. We confirmed this
condition in our study that the patients who
had paronychia also experienced xerosis cutis
(see Fig. 4).
There were no other cutaneous side effects
such as hair changes, mucositis, or drug
hypersensitivity to gefitinib observed in our
patients in this study. Similar results have been
published in other studies of gefitinib
treatment. Hair disorder has once been
reported, by Santiago et al. [5], with one of
seven patients who used erlotinib EGFR
inhibitor experiencing hair growth and texture
alteration. The hair became thin, brittle or
curled. However, none of our participants used
erlotinib.
Transepidermal Water Loss Value
in NSCLC with EGFR Mutation Who
Received Gefitinib
Mean patient TEWL value in this study
increased compared to the normal value range
2.26 ± 1.36 g/m2/h, as a consequence of EGFR
inhibition that might cause abnormal
keratinocyte differentiation resulting in
disturbances of the stratum corneum and
sebaceous glands leading to the loss of the
epidermal water-retaining function [14].
Fig. 3 Xerosis cutis on patient’s upper extremity
Fig. 4 Paronychia of patient’s third toe nail
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Elevation of TEWL was also reported by
Fabbrocini et al. [26] in 33 carcinoma patients
who experienced EGFR inhibitor side effects
(16.67 g/m2/h). However, our study differed
from Fabroccini’s since we carried out
stratification for each patient characteristic
group.
Transepidermal water loss value
measurement in our study participants (see
Table 3) showed a higher value in male
patients (11.64 g/m2/h) compared to females
(10.68 g/m2/h). This might have resulted from
several influencing factors, such as the use of
topical products, exposure to chemicals
(including frequency of exposure to solvents
and detergents/surfactants), and the degree of
skin damage which affected patients skin
hydration state [27]. Moreover, sweat and
sebaceous gland activities were higher in males
[28] and so might have increased the TEWL
value [29]. Similar results have been published
by Reed et al. [30], who showed mean TEWL
values in male patients of 5.1 ± 0.6 g/m2/h and
in female patients of 4.8 ± 0.4 g/m2/h.
Transepidermal water loss value
measurements classified by age group in our
patients showed the highest value in the
40–44 years age group while the lowest one
was in the[65 years age group. This happened
because the participant with the highest TEWL
value who experienced the most severe form of
xerosis cutis was in the 40–44 years age group,
while the one participant who did not
experience skin disorder was included in the
[65 years age group. This condition had an
impact on the participants’ mean TEWL value
in those age groups.
Classified by gefitinib consumption interval,
the lowest TEWL value was found in patients
using gefitinib for less than a month and the
highest in the 5–6 months interval (see Table 3).
As mentioned before, the only patient who had
been using gefitinib for \1 month had not
experienced any cutaneous effects which
might also affect the TEWL value. On the
other hand, one of two patients who has been
on gefitinib therapy for 5–6 months
experienced the most cutaneous side effects
and had the highest TEWL value.
Limitations
The limited number of samples in our study
might not fully reflect the real population
distribution of cutaneous side effects due to
gefitinib treatment. Future studies should be
conducted with longer observation times and
records of both TEWL value measurements and
cutaneous side effects from examinations in the
pre- and post-gefitinib therapy period to
provide better descriptions of EGFR
inhibitior-induced cutaneous side effects.
CONCLUSIONS
Gefitinib has been approved for the treatment
of NSCLC in many countries. However, its use is
associated with cutaneous side effects of varied
severity. Health care providers should
acknowledge and understand that these
conditions can be managed in order to allow
the continuation of the therapy.
Multidisciplinary management is essential to
prevent severe symptoms, to increase patient
compliance, consequently increasing the
survival of patients with a better quality of life.
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